학술논문
DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15280020